Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Jun. 2014, InterMunespent€0.61 Mil on purchasing property, plant, equipment.
It gained€0.00 Mil from selling property, plant, and equipment.
It spent€0.00 Mil on purchasing business.
It gained€0.00 Mil from selling business.
It spent€156.73 Mil on purchasing investments.
It gained€50.12 Mil from selling investments.
It paid€0.00Mil for net Intangibles purchase and sale.
And it paid€0.00 Mil for other investing activities.
In all, InterMunespent€107.22 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Jun. 2014.
InterMune Cash Flow from Investing Historical Data
The historical data trend for InterMune's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
InterMune's Cash Flow from Investing for the fiscal year that ended in Dec. 2013 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €-92.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InterMune (FRA:IUX) Cash Flow from Investing Explanation
InterMune's purchase of property, plant, equipment for the
three
months ended in Jun. 2014 was €-0.61 Mil. It means InterMune spent €0.61 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
InterMune's sale of property, plant, equipment for the
three
months ended in Jun. 2014 was €0.00 Mil. It means InterMune gained €0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
InterMune's purchase of business for the
three
months ended in Jun. 2014 was €0.00 Mil. It means InterMune spent €0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
InterMune's sale of business for the
three
months ended in Jun. 2014 was €0.00 Mil. It means InterMune gained €0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
InterMune's purchase of investment for the
three
months ended in Jun. 2014 was €-156.73 Mil. It means InterMune spent {stock_data.stock.currency_symbol}}156.73 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
InterMune's sale of investment for the
three
months ended in Jun. 2014 was €50.12 Mil. It means InterMune gained €50.12 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
InterMune's net Intangibles purchase and sale for the
three
months ended in Jun. 2014 was €0.00 Mil.
It means InterMune paid €0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
InterMune's cash from discontinued investing activities for the
three
months ended in Jun. 2014 was 0.00 Mil.
It means InterMune paid €0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
InterMune's cash from other investing activities for the
three
months ended in Jun. 2014 was €0.00 Mil.
It means InterMune paid €0.00 Mil for other investing activities.
InterMune Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of InterMune's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:IUX has been successfully added to your 